Items tagged with Medicines

A global perspective on pyrazinamide resistance: systematic review and meta-analysis (post)

Abstract

New publication highlights CPTR’s work on Hollow Fiber System Model for TB (post)

The achievements and ongoing efforts of CPTR’s work on the Hollow Fiber System Model for TB (HFS-TB) are detailed in a new supplement published in the Clinical Infectious Diseases journal. The supplement includes an editorial by EMA on its qualification of this tool to reliably assess the potential efficacy of new drugs and combination regimens, an editorial by FDA supporting the use of this tool in drug development and articles co-authored by members of CPTR’s Preclinical and Clinical Sciences Workgroup. It can be read online here.

Response statement from Sandoz (post)

Due to stability issues impacting the intravenous tuberculosis treatment Rifampicin i.v., we have suspended production of this product. While the company recognizes that it is currently not able to supply the South African market and other markets worldwide with this specific formulation, Sandoz continues to supply Rifampicin in pill form to South African hospitals and healthcare providers. Patients with questions about their specific treatment should speak to a physician or healthcare professional.

Deakin researchers discover potential treatment for tuberculosis (post)

Deakin University scientists have discovered a potential new treatment for tuberculosis, a disease rapidly gaining resistance against current medical therapies.

Plant-based drug can fight resistant TB (post)

• New compounds work by disabling a protective enzyme produced by TB bugs
• The compounds originate from the ellipticine plant-alkaloid family
• Both dormant and highly drug-resistant TB bugs can be dealt with

BANGALORE, December 20, 2015 - Scientists from India and the US say they have discovered a group of compounds that can kill Mycobacterium tuberculosis, the bacterium responsible for causing tuberculosis (TB), by disabling a major defence mechanism it uses to survive in the human body.

Old drugs, new tricks: Medications approved for other uses also have antibiotic action (post)

CHAMPAIGN, Ill. — A number of drugs already approved to treat parasitic infections, cancers, infertility and other conditions also show promise as antibiotic agents against staph and tuberculosis infections, according to a new study by University of Illinois chemists and collaborators. Because these agents act against multiple targets within the bacteria, it may be harder for bacteria to develop resistance.

Phase 1 TBA-354 placed on clinical hold (post)

January 4, 2016 - TB Alliance announced today that it has voluntarily halted further dosing of TBA-354 in the ongoing Multiple Ascending Dose (MAD) Phase 1 study. This action has prompted the United States Food and Drug Administration (FDA) to place the organization’s Investigational New Drug (IND) submission for TBA-354 on clinical hold. TBA-354, which had entered Phase 1 testing in early 2015, is from the nitroimidazole class of chemicals.

FDA faulted for failure to track safety issues with drugs already on market (post)

WASHINGTON — Most Americans assume that drugs approved by the Food and Drug Administration are safe to take as directed. But safety concerns often arise only after the drugs go on the market, when companies or doctors tell the FDA about cases of patients who have fallen ill or died from their medications.

EUPATI launches a new educational Toolbox on Medicines Research & Development for patient advocates (post)

-- More than 100 topics in 7 languages for patient advocates to discover, adapt and share!
-- Online information resource designed to enable more meaningful patient involvement!
-- Information and education to help engage patients and patient advocates!

Slight chemical change may improve TB treatments: study (post)

One small chemical change to an existing antibacterial drug results in a compound that is more effective against its target enzyme in tuberculosis, Vanderbilt researchers have discovered.